Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations

Next Previous
Search
Trial Profile

1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisantaspase (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Dec 2022 Results investigating the impact of short and long acting crisantaspases on circulating levels of plasma amino acids (AAs) other than Gln and Asn using human plasma samples obtained from patients of this study presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 12 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top